X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Cancer Spread Given More Thrust Because of Role of Actin

Content Team by Content Team
2nd February 2023
in Drug Development, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The University of Freiburg researchers have found out that the release of prometastatic factors is influenced by the skeleton of the cell, known as actin.

As per a research team that was led by Dr. Robert Grosse and Dr. Carsten Schwan, the actin molecules’ transportation with the skeleton of the cell is one of the major influencing factors when it comes to the spread of cancer metastatically.

Metastases take place when the cancer cells leave the primary tumour and spread across the body. In order to make this happen, the cells have to initially break contact with their neighbouring cells and then move to other tissues. The entire process is aided by the signalling molecules that get released by the cancerous cells, which thereby increase the tumour’s malignancy.

Advance Science is the journal where this study has been published.

Actin filaments are a part of the skeleton of the cell and happen to be very important for stability as well as mobility. The actin forms a network, which is built and broken down because of either the addition or detachment of the building blocks right at the filament’s end.

This process happens to be regulated with the aid of other molecules known as formins. The network of Actin aids in the movement of cells across the body, typically for instance in wound closure and the same process also takes place in the cancer spreading cells. Actin also helps in the transportation of substances that happen to be within the cells.

The researchers went on to discover that the network of actin brings about the release of prometastatic elements. In the research the scientists made use of high-resolution microscopy that tracked the movement of the transport vesicles which were individual inside the living cancer cells. As per Dr. Grosse, they observed that vesicles that were loaded with ANGPTL-4 were conveyed to the cell periphery by means of localised and dynamic polymerization of actin filaments.

Notably, ANGPTL-4 is the one that promotes metastasis formation across various cancer types and happens to be a significant premetastatic factor.

The microscopic observation of the researchers as well as their genetic analysis led them to conclude that vesicle movement was controlled through the formin-like molecule FMNL2 by way of polymerization, which describes the actin filament elongation within the vesicle.

Grosse says that they already knew that the surge in FMNL2 activity had prometastatic effects across many types of tumours and that, in their current work, they could now demonstrate a significant underlying process as well as connect to the signalling pathway pertaining to TGF-beta signalling.

The scientists opine that this knowledge can be very well used when it comes to tumour diagnosis and therapy. The findings could very well aid in the creation of an antibody capable of indicating the existence of FMNL2 that is active and aiming at phosphorylated FMNL2. The research is a part of a study series from CIBSS, which is on a quest to achieve an absolute understanding of biological signalling processes. The scientists would do better to gauge the individual molecules’ and cells’ interactions, as well as the processes that take place across organisms and organs. As per the researchers, the gained knowledge will be used in developing strategies to control signals in a more targeted way. The new tech can also enable them to get new insights when it comes to research and create innovations in medicine and plant sciences.

Previous Post

UK Into Thailand Genomic Collaboration On Health Threats

Next Post

Singapore Research & Innovation Gets A Push Of $50mn Funding

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

Singapore Research & Innovation Gets A Push Of $50mn Funding

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In